NCT-05472623

Phase 2 Trial of Neoadjuvant KRAS G12C directed therapy with Adagrasib (MRTX849) with or without Nivolumab in Resectable Non-Small Cell Lung Cancer (Neo-KAN)

In the Neo-KAN Phase 2 trial, researchers are exploring the use of Adagrasib (MRTX849), a targeted therapy aimed at the KRAS G12C mutation, before surgery in patients with non-small cell lung cancer. Some patients will receive Adagrasib alone, while others will receive it in combination with Nivolumab, a type of immunotherapy. The goal is to assess the effectiveness and safety of these treatments in preparing patients for surgical removal of their lung cancer.

Phase 2 trial: An advanced point of testing, where they're trying to confirm if a treatment works well.

KRAS: A KRAS mutation is a specific type of alteration in the KRAS gene, which is part of the RAS gene family. These mutations can lead to uncontrolled cell growth and are commonly found in various cancers, impacting treatment outcomes and guiding therapeutic strategies.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05472623

Clinical Trial Site: Columbia

To see all available clinical trials click here.